Indoleamine 2,3-dioxygenase and tumor-induced tolerance

David H. Munn, Andrew L. Mellor

Research output: Contribution to journalReview article

698 Citations (Scopus)

Abstract

Tumors arise from normal cells of the body through genetic mutation. Although such genetic mutation often leads to the expression of abnormal antigens, the immune system fails to respond effectively to these antigens; that is, it is tolerant of these antigens. This acquired state of tolerance must be overcome for cancer immunotherapy to succeed. Indoleamine 2,3-dioxygenase (IDO) is one molecular mechanism that contributes to tumor-induced tolerance. IDO helps create a tolerogenic milieu in the tumor and the tumor-draining lymph nodes, both by direct suppression of T cells and enhancement of local Treg-mediated immunosuppression. It can also function as an antagonist to other activators of antitumor immunity. Therefore, strategies to block IDO might enhance the effectiveness of tumor immunotherapy.

Original languageEnglish (US)
Pages (from-to)1147-1154
Number of pages8
JournalJournal of Clinical Investigation
Volume117
Issue number5
DOIs
StatePublished - May 1 2007

Fingerprint

Indoleamine-Pyrrole 2,3,-Dioxygenase
Neoplasms
Antigens
Immunotherapy
Mutation
Immunosuppression
Immune System
Immunity
Lymph Nodes
T-Lymphocytes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Indoleamine 2,3-dioxygenase and tumor-induced tolerance. / Munn, David H.; Mellor, Andrew L.

In: Journal of Clinical Investigation, Vol. 117, No. 5, 01.05.2007, p. 1147-1154.

Research output: Contribution to journalReview article

Munn, David H. ; Mellor, Andrew L. / Indoleamine 2,3-dioxygenase and tumor-induced tolerance. In: Journal of Clinical Investigation. 2007 ; Vol. 117, No. 5. pp. 1147-1154.
@article{12106d3e02354713963f37a2f7b06e2f,
title = "Indoleamine 2,3-dioxygenase and tumor-induced tolerance",
abstract = "Tumors arise from normal cells of the body through genetic mutation. Although such genetic mutation often leads to the expression of abnormal antigens, the immune system fails to respond effectively to these antigens; that is, it is tolerant of these antigens. This acquired state of tolerance must be overcome for cancer immunotherapy to succeed. Indoleamine 2,3-dioxygenase (IDO) is one molecular mechanism that contributes to tumor-induced tolerance. IDO helps create a tolerogenic milieu in the tumor and the tumor-draining lymph nodes, both by direct suppression of T cells and enhancement of local Treg-mediated immunosuppression. It can also function as an antagonist to other activators of antitumor immunity. Therefore, strategies to block IDO might enhance the effectiveness of tumor immunotherapy.",
author = "Munn, {David H.} and Mellor, {Andrew L.}",
year = "2007",
month = "5",
day = "1",
doi = "10.1172/JCI31178",
language = "English (US)",
volume = "117",
pages = "1147--1154",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "5",

}

TY - JOUR

T1 - Indoleamine 2,3-dioxygenase and tumor-induced tolerance

AU - Munn, David H.

AU - Mellor, Andrew L.

PY - 2007/5/1

Y1 - 2007/5/1

N2 - Tumors arise from normal cells of the body through genetic mutation. Although such genetic mutation often leads to the expression of abnormal antigens, the immune system fails to respond effectively to these antigens; that is, it is tolerant of these antigens. This acquired state of tolerance must be overcome for cancer immunotherapy to succeed. Indoleamine 2,3-dioxygenase (IDO) is one molecular mechanism that contributes to tumor-induced tolerance. IDO helps create a tolerogenic milieu in the tumor and the tumor-draining lymph nodes, both by direct suppression of T cells and enhancement of local Treg-mediated immunosuppression. It can also function as an antagonist to other activators of antitumor immunity. Therefore, strategies to block IDO might enhance the effectiveness of tumor immunotherapy.

AB - Tumors arise from normal cells of the body through genetic mutation. Although such genetic mutation often leads to the expression of abnormal antigens, the immune system fails to respond effectively to these antigens; that is, it is tolerant of these antigens. This acquired state of tolerance must be overcome for cancer immunotherapy to succeed. Indoleamine 2,3-dioxygenase (IDO) is one molecular mechanism that contributes to tumor-induced tolerance. IDO helps create a tolerogenic milieu in the tumor and the tumor-draining lymph nodes, both by direct suppression of T cells and enhancement of local Treg-mediated immunosuppression. It can also function as an antagonist to other activators of antitumor immunity. Therefore, strategies to block IDO might enhance the effectiveness of tumor immunotherapy.

UR - http://www.scopus.com/inward/record.url?scp=34248173331&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34248173331&partnerID=8YFLogxK

U2 - 10.1172/JCI31178

DO - 10.1172/JCI31178

M3 - Review article

C2 - 17476344

AN - SCOPUS:34248173331

VL - 117

SP - 1147

EP - 1154

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 5

ER -